The reading room keeps the sources within reach

A quick way to read the shelf

An animal experiment, a small human safety study and an FDA document answer different questions. None becomes a treatment recommendation just by appearing on this page. Look for the substance, who or what was studied, and what changed.

Keep the preparation attached

A fragment isn’t the full protein. A cream isn’t an injection. A study of one ingredient isn’t a trial of a blend. Those details still matter when a review gathers several papers together.

Dates need care too

FDA’s safety-risk page is marked current April 22, 2026. It lists withdrawn nominations without giving the individual withdrawal dates. Withdrawal isn’t approval. The access documents explain rules and safety concerns, rather than proving a benefit.

Read the part you came for

You don’t need to work through every source. Follow one finding back to its paper. If our account reaches further than the source does, the contact page explains how to flag the exact mismatch.

Sources used in these rooms

• The rat Achilles-tendon experiment from 2003

  Cut Achilles tendons and tendon cells in rats; this wasn’t a human injury trial.

• Vessel-growth signals across three experimental settings

  Blood-vessel-growth research in chick membranes, rat limbs and cells grown in a lab.

• The 2025 intravenous pilot with two adults

  Two adults with prior intravenous BPC-157 exposure took part in an uncontrolled safety pilot. It didn’t test injury recovery.

• FDA examines BPC-157 chemistry and clinical gaps

  FDA reviews the chemical forms, limited human evidence and safety questions around BPC-157.

• FDA separates TB-500 from the longer protein

  FDA separates capped TB-500 from related peptides and reviews the missing human evidence.

• A safety study of full-length thymosin beta-4

  A short safety study of full-length thymosin beta-4 in healthy volunteers, not the TB-500 fragment.

• The 2015 review connecting GHK and skin research

  A review of GHK and skin research. Some cosmetic reports it cites weren’t full journal papers.

• A 2025 review asks whether topical GHK reaches its target

  A review of getting GHK through skin, including the shortage of clinical studies.

• Copper-peptide skincare after laser resurfacing in 2006

  Thirteen people completed this post-laser study. The GHK-Cu group reported higher satisfaction; objective assessments found no statistically significant added skin-quality benefit.

• Copper-tripeptide penetration in isolated skin

  An experiment measuring copper in isolated skin layers, not a treatment trial in people.

• The 2008 KPV study centred on intestinal uptake

  KPV uptake and inflammation in intestinal cells and mice, rather than patients receiving treatment.

• Carrier particles deliver KPV in a 2017 mouse study

  KPV in carrier particles held in a gel was given by mouth to mice with bowel inflammation. The preparation matters.

• FDA considers KPV evidence and missing safety tests

  FDA’s KPV review found no human exposure studies and gaps in animal safety testing.

• FDA keeps its safety concerns beside withdrawn nominations

  FDA’s safety concerns remain beside withdrawn nominations; the GHK-Cu entry specifically concerns injections.

• FDA explains the checks compounded medicines have not undergone

  FDA explains why compounded medicines aren’t FDA-approved and what it hasn’t checked before marketing.

• HHS explains where a telehealth professional needs authority to practise

  HHS explains state licensure requirements for online care, including where the patient is located.